Gilead Sciences, Inc., a research-based biopharmaceutical
company, discovers, develops, and commercializes medicines in areas of unmet
medical needs in North America, South America, Europe, and the Asia-Pacific.
The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla,
Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human
immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread,
and Hepsera products for the treatment of liver diseases. It also offers
Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the
treatment of certain blood cancers; Letairis, an endothelin receptor antagonist
for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for
the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a
pharmacologic stress agent in radionuclide myocardial perfusion imaging;
Cayston, an inhaled antibiotic for the treatment of respiratory systems in
cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the
treatment and prevention of influenza A and B. In addition, the company
provides other products, such as AmBisome, an antifungal agent to treat serious
invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to
treat neovascular age-related macular degeneration. Further, it has product
candidates in various stages of development for the treatment of HIV/AIDS and
liver diseases, such as hepatitis B virus and hepatitis C virus;
inflammation/oncology; serious cardiovascular; and respiratory conditions, as
well as diabetic nephropathy and ebola. The company markets its products
through its commercial teams and/or in conjunction with third-party
distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements
with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc.,
and Galapagos NV. The company was founded in 1987 and is headquartered in
Foster City, California.
GILD doesn't have any long dividend payment history, because it has paid dividends only 5 quarters and made only 1 dividend increase so far. After the last dividend increase declaration, Gilead Sciences Inc. now pays dividends of $0.47 per share normally in March, June, September and December.
Details of my purchase:
Some ratings for GILD:
Yahoo: Mean Recommendation
2.1, 1y Target Est $110.89
Reuters:
Mean Rating 2.08
Morningstar:
(*****)
At today's exchange rate, this purchase 20 shares of GILD
will increase €25.33 ($28.01) of my expected annual net dividend income and
will increase my portfolio's projected annual net dividend income to €9550.00. With
purchase price $79.89 plus commission ($5.00) my starting yield on cost is 2.35%.
Click here
to see my portfolio.
Full Disclosure: Long GILD
No comments:
Post a Comment